| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Fat Loss Rauwolscine demonstrates alpha-2 adrenergic receptor antagonist activity in preclinical binding studies, with potentially greater potency than yohimbine at this receptor. No human clinical trials have directly evaluated rauwolscine for fat loss; efficacy is extrapolated from yohimbine data and receptor pharmacology. | Changes; see studies | Small effect |
Supplement
Rauwolscine, also called alpha-yohimbine, is a plant compound that blocks alpha-2 adrenergic receptors, which normally brake the release of stress-signalling chemicals. People mostly look at it for fat loss, but no human trials have tested that, and lab binding studies only showed it blocks this receptor, possibly more strongly than yohimbine. The only other work was one 1964 study on the sympathetic nervous system, so the evidence is very limited and largely borrowed from yohimbine.
Sources: PMID 14132149
- Updated
- How we grade
- 1 study cited
- Best evidence
- Grade D
- Conditions studied
- 2
- Outcomes
- 2
- Graded outcomes
- 0002
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Sympathetic Nervous System Activity A 1964 preclinical study examined the effects of 3-epi-alpha-yohimbine (rauwolscine) on the sympathetic nervous system, consistent with its known alpha-2 adrenergic antagonist mechanism. Evidence is limited to this single early pharmacological investigation with no modern human replication. | Improves (the measure goes up) | Small effect | 1 study | |||
Studies that measured sympathetic nervous system activity | ||||||
Key findings
- Sympathetic Nervous System ActivityImproves (the measure goes up)
- Fat LossChanges; see studies
Studies cited
1 study from PubMed